Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Viking Therapeutics Inc
VKTX | US
33.61
USD0.63
1.91%
VKTX | US
About Viking Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
33.61
Open
32.87
High
33.80
Low
32.51
Viking Therapeutics Inc. a clinical-stage biopharmaceutical company focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809 an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß) which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis as well as NAFLD. It also develops VK5211 an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612 an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735 a novel dual agonist of the glucagon-like peptide which is in Phase 1 SAD/MAD clinical trial and VK0214 an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego California.
View LessVKTX | US
Risk
62.0
Sharpe
0.15
Luna's Score
46/100
Recommendation
Hold
Luna says (VKTX | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
67.3%1 month
62.0%3 months
63.8%6 months
66.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
7.87
Debt to equity
0.00
Debt to assets
0.00
Ent. to EBITDA
-71.64
Ent. to rev.
-
PEG
-0.03
Other Fundamentals
EBITDA
-
MarketCap
3.72B
MarketCap(USD)
3.72B
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-14.80
Short ratio
4.58
Short perc.
17.59
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
5.54
Range1M
8.56
Range3M
13.31
Volumes: Market Activity
Rel. volume
0.68
Price X volume
64.38M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -71.64 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 7.87 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 63.76 | 72.80 | Par |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 3.72B | 3.66B | Par |
